Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Gomez

Undersea and Hyperbaric Medicine Calhoun, GA Medical Doctor

NPI 1447319975 CMS profile 337563

1035 Red Bud Rd Ne, Calhoun, GA 30701

Open in the dashboard

General payments

$1,488

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Gomez of Calhoun, GA is reported in the CMS Open Payments database as having received $1,488 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $221 12
2024 General $212 20
2023 General $273 12
2022 General $198 7
2021 General $253 6
2020 General $77 5
2019 General $255 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Gomez
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Jose Gomez were reported at $221. Among 65 Undersea and Hyperbaric Medicine profiles paid that year, the median was $153 and the middle half received between $68 and $340.

Show as a table
Year Jose Gomez Undersea and Hyperbaric Medicine median Middle half National median
2019 $255 $162 $85–$376 $163
2020 $77 $111 $46–$307 $114
2021 $253 $154 $50–$306 $132
2022 $198 $122 $40–$378 $149
2023 $273 $145 $52–$410 $160
2024 $212 $146 $80–$316 $164
2025 $221 $153 $68–$340 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $469 28 payments
  2. Stryker Corporation $182 2 payments
  3. PolyMedics Innovations Inc $141 5 payments
  4. Smith+Nephew, Inc. $132 8 payments
  5. Triad Life Sciences Inc. $101 1 payment
  6. KCI USA, Inc $79 4 payments
  7. ConvaTec Inc. $53 3 payments
  8. ETS Wound Care LLC $46 4 payments
  9. Hollister Incorporated $44 2 payments
  10. Melinta Therapeutics, Inc. $33 2 payments
  11. Other $209 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,330 69 payments
  2. Travel and Lodging $93 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $65 1 payment
Products named General payments · program years 2019–2025
  1. XIA 3 $161 1 payment
  2. INNOVAMATRIX AC $101 1 payment
  3. Puraply, NuShield, Affinity $93 1 payment
  4. Puraply $75 4 payments
  5. Apligraf $65 1 payment
  6. Dermagraft $65 1 payment
  7. Puraply/Affinity/NuTech $65 1 payment
  8. Affinity $62 5 payments
  9. GRAFIX $55 3 payments
  10. MIRRAGEN ADVANCED WOUND MATRIX $46 4 payments
  11. Other $769 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

261

Median for Preventive Medicine: 100

Drug cost

$2,029

Median for Preventive Medicine: $5,055

Branded share of claims

18.4%

Median for Preventive Medicine: 27.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linezolid Generic 24 $1,079
Ciprofloxacin Hcl Generic 63 $282
Doxycycline Hyclate Generic 53 $260
Levofloxacin Generic 73 $226
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 21 $97
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 27 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$126,745

Medicare's payments for the services billed

Medicare patients

126

Average age 77

Services billed

2,415

68 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 56%
Heart failure 54%
Chronic kidney disease 47%
Ischemic heart disease 40%
Atrial fibrillation 40%
Depression 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record